Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema

Marc A. Riedl, William R. Lumry, H. Henry Li, Timothy Craig, David Fitts, Ira Kalfus, Marc E. Uknis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Laryngeal edema is a life-threatening manifestation of hereditary angioedema (HAE), an autosomal-dominant disorder caused by quantitative or functional C1 esterase inhibitor (C1 INH) deficiency. The preparation of nanofiltered C1 INH (C1 INH-nf) used in this study is indicated for routine prophylaxis against angioedema attacks in the United States and for treatment, preprocedure prevention, and routine prevention of HAE in Europe. The objective of this analysis was to evaluate the effectiveness and tolerability of C1 INH-nf when used for the treatment of laryngeal attacks. Methods: A post hoc analysis of an open-label treatment study evaluated the effectiveness of C1 INH-nf in the treatment of laryngeal attacks in patients with HAE. Outcomes included unequivocal or clinical relief rates and time from treatment to onset of relief. Data were compiled from this and three other studies for post hoc dosing and tolerability analyses. In all studies, C1 INH-nf at 1000 U was administered i.v., with a second 1000-U dose given after 60 minutes if indicated. Results: In the open-label treatment study, 60 (50/84) and 77% (65/84) of attacks achieved unequivocal relief within 1 and 4 hours, respectively, after treatment. Time to unequivocal relief was shorter with prompt treatment. When C1 INH-nf was administered within 4 hours of symptom onset, clinical relief was achieved in 94% (45/48) of attacks within 4 hours after treatment. Of 265 attacks from the four studies, 62% received two 1000-U doses of C1 INH-nf. No serious adverse events occurring within 7 days after treatment were attributed to study drug, and only one patient required intubation after receiving C1 INH-nf (14.5 hours after symptom onset). Conclusion: This analysis supports that C1 INH-nf is an effective and well-tolerated therapy for laryngeal angioedema attacks.

Original languageEnglish (US)
Pages (from-to)517-521
Number of pages5
JournalAmerican Journal of Rhinology and Allergy
Volume27
Issue number6
DOIs
StatePublished - Nov 1 2013

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Therapeutics
Angioedema
Laryngeal Edema
Intubation

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Riedl, Marc A. ; Lumry, William R. ; Li, H. Henry ; Craig, Timothy ; Fitts, David ; Kalfus, Ira ; Uknis, Marc E. / Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. In: American Journal of Rhinology and Allergy. 2013 ; Vol. 27, No. 6. pp. 517-521.
@article{4257af8a6545497dac539274f6efdaf9,
title = "Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema",
abstract = "Background: Laryngeal edema is a life-threatening manifestation of hereditary angioedema (HAE), an autosomal-dominant disorder caused by quantitative or functional C1 esterase inhibitor (C1 INH) deficiency. The preparation of nanofiltered C1 INH (C1 INH-nf) used in this study is indicated for routine prophylaxis against angioedema attacks in the United States and for treatment, preprocedure prevention, and routine prevention of HAE in Europe. The objective of this analysis was to evaluate the effectiveness and tolerability of C1 INH-nf when used for the treatment of laryngeal attacks. Methods: A post hoc analysis of an open-label treatment study evaluated the effectiveness of C1 INH-nf in the treatment of laryngeal attacks in patients with HAE. Outcomes included unequivocal or clinical relief rates and time from treatment to onset of relief. Data were compiled from this and three other studies for post hoc dosing and tolerability analyses. In all studies, C1 INH-nf at 1000 U was administered i.v., with a second 1000-U dose given after 60 minutes if indicated. Results: In the open-label treatment study, 60 (50/84) and 77{\%} (65/84) of attacks achieved unequivocal relief within 1 and 4 hours, respectively, after treatment. Time to unequivocal relief was shorter with prompt treatment. When C1 INH-nf was administered within 4 hours of symptom onset, clinical relief was achieved in 94{\%} (45/48) of attacks within 4 hours after treatment. Of 265 attacks from the four studies, 62{\%} received two 1000-U doses of C1 INH-nf. No serious adverse events occurring within 7 days after treatment were attributed to study drug, and only one patient required intubation after receiving C1 INH-nf (14.5 hours after symptom onset). Conclusion: This analysis supports that C1 INH-nf is an effective and well-tolerated therapy for laryngeal angioedema attacks.",
author = "Riedl, {Marc A.} and Lumry, {William R.} and Li, {H. Henry} and Timothy Craig and David Fitts and Ira Kalfus and Uknis, {Marc E.}",
year = "2013",
month = "11",
day = "1",
doi = "10.2500/ajra.2013.27.3973",
language = "English (US)",
volume = "27",
pages = "517--521",
journal = "American Journal of Rhinology and Allergy",
issn = "1945-8924",
publisher = "OceanSide Publications Inc.",
number = "6",

}

Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. / Riedl, Marc A.; Lumry, William R.; Li, H. Henry; Craig, Timothy; Fitts, David; Kalfus, Ira; Uknis, Marc E.

In: American Journal of Rhinology and Allergy, Vol. 27, No. 6, 01.11.2013, p. 517-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema

AU - Riedl, Marc A.

AU - Lumry, William R.

AU - Li, H. Henry

AU - Craig, Timothy

AU - Fitts, David

AU - Kalfus, Ira

AU - Uknis, Marc E.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: Laryngeal edema is a life-threatening manifestation of hereditary angioedema (HAE), an autosomal-dominant disorder caused by quantitative or functional C1 esterase inhibitor (C1 INH) deficiency. The preparation of nanofiltered C1 INH (C1 INH-nf) used in this study is indicated for routine prophylaxis against angioedema attacks in the United States and for treatment, preprocedure prevention, and routine prevention of HAE in Europe. The objective of this analysis was to evaluate the effectiveness and tolerability of C1 INH-nf when used for the treatment of laryngeal attacks. Methods: A post hoc analysis of an open-label treatment study evaluated the effectiveness of C1 INH-nf in the treatment of laryngeal attacks in patients with HAE. Outcomes included unequivocal or clinical relief rates and time from treatment to onset of relief. Data were compiled from this and three other studies for post hoc dosing and tolerability analyses. In all studies, C1 INH-nf at 1000 U was administered i.v., with a second 1000-U dose given after 60 minutes if indicated. Results: In the open-label treatment study, 60 (50/84) and 77% (65/84) of attacks achieved unequivocal relief within 1 and 4 hours, respectively, after treatment. Time to unequivocal relief was shorter with prompt treatment. When C1 INH-nf was administered within 4 hours of symptom onset, clinical relief was achieved in 94% (45/48) of attacks within 4 hours after treatment. Of 265 attacks from the four studies, 62% received two 1000-U doses of C1 INH-nf. No serious adverse events occurring within 7 days after treatment were attributed to study drug, and only one patient required intubation after receiving C1 INH-nf (14.5 hours after symptom onset). Conclusion: This analysis supports that C1 INH-nf is an effective and well-tolerated therapy for laryngeal angioedema attacks.

AB - Background: Laryngeal edema is a life-threatening manifestation of hereditary angioedema (HAE), an autosomal-dominant disorder caused by quantitative or functional C1 esterase inhibitor (C1 INH) deficiency. The preparation of nanofiltered C1 INH (C1 INH-nf) used in this study is indicated for routine prophylaxis against angioedema attacks in the United States and for treatment, preprocedure prevention, and routine prevention of HAE in Europe. The objective of this analysis was to evaluate the effectiveness and tolerability of C1 INH-nf when used for the treatment of laryngeal attacks. Methods: A post hoc analysis of an open-label treatment study evaluated the effectiveness of C1 INH-nf in the treatment of laryngeal attacks in patients with HAE. Outcomes included unequivocal or clinical relief rates and time from treatment to onset of relief. Data were compiled from this and three other studies for post hoc dosing and tolerability analyses. In all studies, C1 INH-nf at 1000 U was administered i.v., with a second 1000-U dose given after 60 minutes if indicated. Results: In the open-label treatment study, 60 (50/84) and 77% (65/84) of attacks achieved unequivocal relief within 1 and 4 hours, respectively, after treatment. Time to unequivocal relief was shorter with prompt treatment. When C1 INH-nf was administered within 4 hours of symptom onset, clinical relief was achieved in 94% (45/48) of attacks within 4 hours after treatment. Of 265 attacks from the four studies, 62% received two 1000-U doses of C1 INH-nf. No serious adverse events occurring within 7 days after treatment were attributed to study drug, and only one patient required intubation after receiving C1 INH-nf (14.5 hours after symptom onset). Conclusion: This analysis supports that C1 INH-nf is an effective and well-tolerated therapy for laryngeal angioedema attacks.

UR - http://www.scopus.com/inward/record.url?scp=84890944763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890944763&partnerID=8YFLogxK

U2 - 10.2500/ajra.2013.27.3973

DO - 10.2500/ajra.2013.27.3973

M3 - Article

VL - 27

SP - 517

EP - 521

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

SN - 1945-8924

IS - 6

ER -